{"id":"bnp7787","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2104318","moleculeType":"Small molecule","molecularWeight":"326.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BNP7787 (also known as mesna derivative) acts as a selective cytoprotective agent by forming a complex with cisplatin that prevents the drug from damaging normal tissues, particularly the kidneys and peripheral nerves. The complex allows cisplatin to retain its anti-cancer activity against tumor cells while reducing dose-limiting toxicities. This mechanism enables higher cisplatin doses or improved tolerability in chemotherapy regimens.","oneSentence":"BNP7787 is a cytoprotective agent that binds to and inactivates cisplatin, reducing its nephrotoxicity and neurotoxicity while preserving anti-tumor efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:47:18.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of cisplatin-induced nephrotoxicity and neurotoxicity in patients receiving cisplatin-based chemotherapy"}]},"trialDetails":[{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT05456256","phase":"PHASE2","title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-03-01","conditions":"Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung","enrollment":90},{"nctId":"NCT00966914","phase":"PHASE3","title":"Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin","status":"COMPLETED","sponsor":"BioNumerik Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Non-small Cell Lung Cancer","enrollment":540},{"nctId":"NCT00039780","phase":"PHASE3","title":"Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel","status":"COMPLETED","sponsor":"BioNumerik Pharmaceuticals, Inc.","startDate":"2001-09","conditions":"Breast Neoplasms, Breast Diseases, Metastases, Neoplasm","enrollment":764},{"nctId":"NCT00077311","phase":"PHASE2","title":"Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-08","conditions":"Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer","enrollment":160},{"nctId":"NCT00003569","phase":"","title":"Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-03","conditions":"Head and Neck Cancer, Lung Cancer, Neurotoxicity","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"MENTAL STATUS CHANGES"},{"count":1,"reaction":"MYOCARDIAL ISCHAEMIA"},{"count":1,"reaction":"PNEUMONIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BNP7787 also known as Tavocept"],"phase":"phase_3","status":"active","brandName":"BNP7787","genericName":"BNP7787","companyName":"Alliance for Clinical Trials in Oncology","companyId":"alliance-for-clinical-trials-in-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BNP7787 is a cytoprotective agent that binds to and inactivates cisplatin, reducing its nephrotoxicity and neurotoxicity while preserving anti-tumor efficacy. Used for Reduction of cisplatin-induced nephrotoxicity and neurotoxicity in patients receiving cisplatin-based chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}